Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Cancer J
Päätekijät: Zhu, Yuan Xiao, Shi, Chang-Xin, Bruins, Laura A., Wang, Xuewei, Riggs, Daniel L., Porter, Brooke, Ahmann, Jonathan M., de Campos, Cecilia Bonolo, Braggio, Esteban, Bergsagel, P. Leif, Stewart, A. Keith
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6370766/
https://ncbi.nlm.nih.gov/pubmed/30741931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0173-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia